from ACAD Homepage Website:
We hold worldwide rights to pimavanserin and have established a patent portfolio, which includes
numerous issued patents covering pimavanserin in the United States, Europe and several additional countries.
We believe that pimavanserin also has the potential to address a range of other neurological and psychiatric disorders that are under served by currently available anti psychotics and represent large unmet medical needs. This may include treatment for psychoses associated with other neurological disorders, including Alzheimer’s disease, and as a co-therapy for schizophrenia
see ya there
thanks for the cheap shares guys.
great read and thanks for sharing too cheap to ignore, bought.
was $8.71 on Thurs. then Fri options did keep it down, now back to filling up the gap.
The Street Insider
2/28/14 (GRPN ) Deutsche Bank Makes Positive Comments on Groupon, Inc. (GRPN)
Deutsche Bank reiterated a Buy rating on Groupon, Inc. (NASDAQ: GRPN) with a price target of $12.00. Analyst Ross Sandler noted the turn-around was "bumpy" but he doesn't think the wheels have come off, and he sees Q1 re-accelerating.
"We recently spent time with GRPN management and came away feeling a lot better about interpretation of
the mixed 4Q, and overall trends heading into 2014. GRPN is facing headwinds in NA as it shifts its inventory from urgent-expiration to perpetual-marketplace deals.